Oncolytics Biotech (NASDAQ:ONCY) Price Target Raised to $10.00

Oncolytics Biotech (NASDAQ:ONCY) had its price target increased by HC Wainwright from $5.00 to $10.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2025 earnings at ($0.25) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at ($0.22) EPS and FY2029 earnings at ($0.04) EPS.

A number of other brokerages have also recently commented on ONCY. Wall Street Zen cut shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Zacks Research raised Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Wednesday, October 8th. Finally, Lake Street Capital initiated coverage on Oncolytics Biotech in a report on Wednesday, August 13th. They issued a “buy” rating and a $7.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.25.

Oncolytics Biotech Price Performance

Shares of ONCY stock opened at $1.04 on Monday. The stock has a market capitalization of $104.38 million, a PE ratio of -3.85 and a beta of 1.32. The business’s 50 day simple moving average is $1.21 and its 200 day simple moving average is $0.96. Oncolytics Biotech has a one year low of $0.33 and a one year high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. As a group, research analysts expect that Oncolytics Biotech will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Oncolytics Biotech

Hedge funds have recently added to or reduced their stakes in the stock. Seeds Investor LLC increased its holdings in Oncolytics Biotech by 17.8% during the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock worth $173,000 after purchasing an additional 33,826 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Oncolytics Biotech during the third quarter valued at approximately $535,000. Finally, Scientech Research LLC bought a new stake in Oncolytics Biotech during the third quarter worth $25,000. Institutional investors and hedge funds own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.